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S U M M A R Y
Background: Mannose-binding lectin (MBL) is a collagen-like serum protein that plays an important role
in ﬁrst-line host defense, especially in infants and young children. The objective of this study was to
explore the genetic polymorphisms and serum protein levels of MBL in Chinese pediatric patients with
common infectious diseases, including recurrent respiratory infection (RRI), acute respiratory infection
(ARI), active cytomegalovirus (CMV) infection, localized abscess, and otitis media.
Methods: MBL genetic polymorphisms of 151 pediatric patients with infectious diseases and 105 healthy
controls were detected by PCR and sequencing. Serum MBL levels of all the patients and controls were
measured using a Human MBL ELISA Kit. Differences in MBL genetic polymorphisms and serum levels
between patients and controls were analyzed by statistical methods.
Results: The frequencies of allele H/L at position 550 of the promoter and three haplotypes – HYPA,
HYPB, and LYPB – were statistically different between patients and controls (p < 0.05). The frequencies
of genotypes ‘YA’ and ‘XB’, relevant to serum protein levels, were also signiﬁcantly different between
patients and controls (p < 0.05). Serum MBL levels of patients with active CMV infection were
signiﬁcantly lower than those of controls (p < 0.05). Conversely, serum MBL levels of patients with ARI
and localized abscess were signiﬁcantly higher than those of controls (p < 0.05).
Conclusions: Genetic polymorphisms attributable to mutations in the promoter and exon 1 of the MBL2
gene appear to be relatively common in pediatric patients with infectious diseases. Low serum MBL
levels may play a role in the high sensitivity of pediatric CMV infections.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Mannose-binding lectin (MBL), which is also named mannan-
binding lectin, is a collagen-like serum protein that plays an
important role in ﬁrst-line host defence.1 With multiple carbohy-
drate-recognition domains, it is able to bind to sugar groups
displayed on the surfaces of a wide range of microorganisms and
activate the complement system through a distinctive third
pathway, independent of both antibody and the C1 complex.2
The attachment of MBL to microbial surfaces, which is presumed to
induce conformational changes in MBL, allows MBL to initiate
other functions such as phagocytosis and modulation of inﬂam-
matory responses.3
The human MBL-encoding gene, named MBL2, is positioned on
chromosome 10 (10q11.2-q21) and consists of four exons
interrupted by three introns.4 Six single nucleotide polymorphisms
(SNPs) in the MBL2 gene are known to be associated with variations* Corresponding author. Tel.: +86 571 87061007; fax: +86 571 87033296.
E-mail address: chssq@zju.edu.cn (S.-Q. Shang).
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doi:10.1016/j.ijid.2012.01.014in the quantity and/or function of MBL in serum. In exon 1, three
SNPs are present at codons 52, 54, and 57, which are described as
variant alleles D, B, and C, respectively.5 Alleles D, B, and C are
generally grouped together as allele O, and the wild-type is allele A.
The effect of polymorphisms in exon 1 are still being studied, but it
is believed that allele O causes low serum levels of MBL protein and
impairs its biological activity.6 SNPs have also been found in the
promoter region of the MBL2 gene at positions 550 H/L, 221 X/Y,
and +4 P/Q, which can also inﬂuence serum levels of MBL.7
Functional promoter analysis has indicated that three haplotype
variants – HY, LY, and LX – are correlated with high, medium, and
low promoter activity; this was in agreement with serum
measurements.8
It has been proved that low serum MBL levels due to SNPs in the
MBL2 gene are associated with increased susceptibility to and
severity of a variety of infective illnesses, particularly when
immunity is already compromised, such as in infants and young
children, patients with cystic ﬁbrosis, and after chemotherapy and
transplantation.9 However, reports on the association between
MBL and infectious diseases in Chinese pediatric patients are
scarce. The aim of this study was to explore the geneticses. Published by Elsevier Ltd. All rights reserved.
Table 1
Age and gender compositions of patients and controls
Group Number Gender Age (months)
Male Female Minimum Maximum Mean
Infectious patients
RRI 57 36 21 6 144 40.7
ARI 21 11 10 6 60 23.8
CMV infection 50 33 17 1 24 4.9
Localized abscess 13 9 4 6 156 33.0
Otitis media 10 6 4 50 113 76.0
Healthy controls 105 46 59 17 48 27.3
RRI, recurrent respiratory infection; ARI, acute respiratory infection; CMV, cytomegalovirus.
R. Tao et al. / International Journal of Infectious Diseases 16 (2012) e403–e407e404polymorphisms and serum levels of MBL in Chinese pediatric
patients with common infectious diseases, including recurrent
respiratory infection (RRI), acute respiratory infection (ARI), active
cytomegalovirus (CMV) infection, localized abscess, and otitis
media.
2. Materials and methods
2.1. Study population and sample collection
One hundred and ﬁfty-one pediatric patients with common
infectious diseases, hospitalized in the Children’s Hospital of
Zhejiang University School of Medicine from January 2004 to
November 2007, were included in this study. The group of
infectious diseases consisted of 57 cases of RRI, 21 cases of ARI, 50
cases of active CMV infection, 13 cases of localized abscess, and 10
cases of otitis media.
The deﬁnition of ARI was an acute upper or lower respiratory
tract infection with symptoms such as fever, nasal congestion,
throat discomfort, cough, etc. The deﬁnition of RRI in this study,
referring to the national guidelines on pediatric respiratory
diseases of China, was as follows: seven upper and three lower
respiratory tract infections per year for children younger than 2
years, six upper and two lower respiratory tract infections per year
for children 3–5 years old, and ﬁve upper and two lower
respiratory tract infections per year for children older than 6
years. All 50 patients with active CMV infection were seropositive
for CMV-IgM antibody as tested by ELISA, and had single- or
multiple-organ damage, including hepatitis, pneumonitis, throm-
bocytopenia, and involvement of the central nervous system. The
subgroup of localized abscess was made up of 13 pediatric patients
suffering from superﬁcial skin and soft tissue abscesses accompa-
nied by focal heat, ache, and swelling. The deﬁnition of otitis media
in this study was acute bacterial infection of the middle ear, with
fever, ear pain (or ear pulling), temporal hearing loss, and bloody or
greenish-yellow pus draining from the ear.
One hundred and ﬁve healthy controls were randomly selected
from children attending for physical examinations at the same
hospital over the same time interval. Healthy controls had neither
signs of acute infection nor a history of recurrent infection. Both
patients and controls were from the Chinese Han population. The
age and gender compositions of patients and controls are
summarized in Table 1.
After obtaining written consent from the parent or guardian, a
4-ml ethylenediaminetetraacetic acid (EDTA)-anticoagulant blood
sample was obtained from all of the study subjects for DNA
extraction and serum MBL measurement. The study protocol was
approved by the local ethics committee.
2.2. MBL2 genotyping
Genomic DNA was extracted from the blood sample using a
standard phenol–chloroform procedure. Six SNPs in the MBL2 gene(550 G/C, 221 C/G, and +4 C/T in the 50-ﬂanking region, and
codon 52 CGT/TGT, codon 54 GGC/GAC, and codon 57 GGA/GAA in
exon 1) were analyzed using a sequencing-based typing method.
The DNA fragment including the promoter and exon 1, with a
length of 953 bp, was ampliﬁed by PCR using the sense primer 50-
CCT GCC AGA AAG TAG AGA GG-30 and anti-sense primer 50-CCA
GGC AGT TTC CTC TGG AAG G-30. The PCR was performed at 95 8C
for 5 min, followed by 32 cycles consisting of 35 s at 95 8C, 35 s at
59 8C, and 45 s at 72 8C, and a ﬁnal 10 min at 72 8C. The PCR
products were separated by electrophoresis on 2% agarose gels and
visualized by staining with ethidium bromide. Genotypes were
ultimately determined by gene sequencing of the PCR products.
2.3. Serum MBL level measurement
The serum MBL levels of patients and controls were measured
by sandwich enzyme immunoassay using a Human MBL ELISA Kit
(Hycult Biotechnology, Uden, the Netherlands). Diluted samples
and standards were incubated in microtiter wells coated with
mannan at room temperature for 1 h. After washing, the plates
were incubated for 1 h with diluted tracer, followed by incubation
for 1 h with diluted streptavidin–peroxidase conjugate. Color was
developed using tetramethylbenzidine (TMB) substrate solution,
and the reaction was stopped by adding stop solution. The plates
were placed in a spectrophotometer and the absorbance was
measured at 450 nm.
2.4. Statistical analysis
The statistical analysis was performed using SPSS 11.0 software
(SPSS, Chicago, IL, USA), and a p-value of <0.05 was considered
signiﬁcant. The Chi-square test was used to test the null hypothesis
for the distribution of the allele and genotype frequencies between
patients and controls. Comparisons of serum MBL levels were done
using the Mann–Whitney U-test.
3. Results
3.1. Comparison of allelic genotype frequencies between patients
and controls
The allelic genotype frequencies of SNPs in the MBL2 gene of the
patients with infectious diseases and healthy controls are
summarized in Table 2. At position 550 of the promoter, allelic
genotype H/H was predominant in both patients and controls.
There was a signiﬁcant difference in allelic genotype frequency at
position 550 between patients and controls (p = 0.004). At
position 221 of the promoter, allelic genotype Y/Y was
predominant, and allelic genotype X/X was not found. There
was no signiﬁcant difference in allelic genotype frequency at
position 221 between patients and controls. At position +4 of the
promoter, allele Q was only detected in the infectious diseases
group. At position +230 of exon 1, allelic genotype A/A was
Table 2
Comparison of allelic genotype frequencies between patients and controls
Position and allelic genotype Patients
(n = 151),
n (%)
Controls
(n = 105),
n (%)
p-Value
Promoter Position 550 H/H 65 (43.1) 67 (63.8) 0.004
H/L 44 (29.1) 18 (17.1)
L/L 42 (27.8) 20 (19.1)
Position 221 Y/Y 121 (80.1) 92 (87.6) 0.115
Y/X 30 (19.9) 13 (12.4)
Position +4 P/P 142 (94.0) 105 (100) -
P/Q 7 (4.7) 0 (0)
Q/Q 2 (1.3) 0 (0)
Exon 1 Position +230 A/A 101 (66.9) 78 (74.3) 0.438
A/B 45 (29.8) 24 (22.9)
B/B 5 (3.3) 3 (2.8)
Table 3
Comparison of haplotype frequencies between infectious patients and healthy
controls
Haplotype Infectious patients
(n = 302), n (%)
Healthy controls
(n = 210), n (%)
p-Value
HYPA 171 (56.6) 146 (69.5) 0.003
HYPB 2 (0.7) 8 (3.8) 0.027
LYPA 48 (15.9) 29 (13.8) 0.516
LYPB 40 (13.3) 14 (6.7) 0.017
LXPA 17 (5.6) 5 (2.4) 0.075
LXPB 13 (4.3) 8 (3.8) 0.781
LYQA 11 (3.6) 0 (0) -
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frequency was found between patients and controls. At positions
+223 and +239 of exon 1, all the alleles were type A, and no type D
or C were detected in either patients or controls.
3.2. Comparison of haplotype frequencies between patients
and controls
As a result of linkage disequilibrium, there were only seven
haplotypes – HYPA, HYPB, LYPA, LYPB, LXPA, LXPB, and LYQA – in
the MBL2 gene. The haplotype frequencies of the MBL2 gene in the
patients with infectious diseases and healthy controls are
summarized in Table 3. The haplotype HYPA was predominant
in both patients and controls. The frequencies of the haplotypes
HYPA, HYPB, and LYPB were statistically different between the
patients and controls (p = 0.003, 0.027, and 0.017, respectively).Table 4
Comparison of promoter and structural combined genotype frequencies between patie
Genotype Infectious patients
(n = 151), n (%)
YA-type HYPA/HYPA 62 86 (57
HYPA/LYPA 12 
HYPA/LYQA 4 
LYPA/LYPA 3 
LYPA/LYQA 3 
LYQA/LYQA 2 
XB-type HYPA/LXPA 12 65 (43
LYPA/LXPA 1 
HYPA/HYPB 1 
HYPA/LYPB 16 
LYPA/LYPB 13 
LYPB/LYPB 5 
HYPA/LXPB 0 
LYPA/LXPB 13 
LXPA/LYPB 4 3.3. Comparison of promoter and structural combined genotype
frequencies between patients and controls
By combination of the seven haplotypes of the MBL2 gene, there
were 15 promoter and structural combined genotypes in this
study. According to a previous study,10 these genotypes are divided
into two groups, the ‘YA-type’ (homozygously carrying both Y and
A alleles) and the ‘XB-type’ (containing the X or B allele at least
heterozygously). The promoter and structural combined genotype
frequencies of infectious diseases patients and healthy controls are
summarized in Table 4. The genotype HYPA/HYPA was predomi-
nant in both patients and controls. The frequencies of the ‘YA-type’,
related to higher serum MBL levels, and the ‘XB-type’, related to
lower serum MBL levels, were signiﬁcantly different between
patients and controls (p = 0.041).
3.4. Comparison of serum MBL levels between patients and controls
The distributions of serum MBL level frequencies in patients
and controls were both characterized by a skewed distribution
(Figure 1). Serum MBL levels of the patients with infectious
diseases ranged from 1 to 7110 ng/ml, with a median of 1110 ng/
ml, and serum MBL levels of the healthy controls ranged from 3 to
6025 ng/ml, with a median of 1065 ng/ml. The minimum,
maximum, median, and percentiles of serum MBL for each group
are summarized in Table 5. Serum MBL levels of the patients with
active CMV infection were signiﬁcantly lower than those of
controls (p = 0.019). Conversely, serum MBL levels of the patients
with ARI and localized abscess were signiﬁcantly higher than those
of controls (p = 0.030, p = 0.021, respectively).
4. Discussion
Among the four exons of the structural MBL2 gene, mutations in
only exon 1 have so far been conﬁrmed to be responsible for serum
protein levels. The frequencies of these mutations are different in
various populations. The variant allele B occurs in 22–28% of
Eurasian populations, whereas the variant allele C is characteristic
of sub-Saharan African populations in whom it reaches frequencies
of 50–60%. The variant allele D reaches frequencies of 14% in
European populations, but can be much lower elsewhere.11 In this
study, only a mutation at position +230 (allele B) was detected,
consistent with the results of previous studies that have found
alleles C and D to be extremely low and nearly absent in the
Chinese population.12,13nts and controls
Healthy controls
(n = 105), n (%)
p-Value
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Figure 1. Distributions of serum MBL level frequencies in (A) healthy controls and (B) patients with infectious diseases.
Table 5
Serum mannose-binding lectin levels of patients and controls (ng/ml)
Group Number Minimum Maximum Median Percentile p-Valuea
P5 P25 P75 P95
Infectious patients
RRI 57 1 3633 798 1 295 1552 2345 0.052
ARI 21 214 6012 1477 242 1015 1746 5902 0.030
CMV infection 50 23 3270 780 60 388 1319 3168 0.019
Localized abscess 13 192 7110 1707 192 907 3168 7110 0.021
Otitis media 10 334 5276 1779 334 674 2497 5276 0.068
Healthy controls 105 3 6025 1065 162 862 1452 2623
RRI, recurrent respiratory infection; ARI, acute respiratory infection; CMV, cytomegalovirus.
a Compared with the group of healthy controls.
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gene in the present study showed that there was a signiﬁcant
difference in allelic genotype frequency at position 550 between
patients and controls (p = 0.004). This ﬁnding indicates that the
genetic reason for the low MBL protein level relative to infections
can be traced back to the mutation of a single nucleotide. On the
other hand, there was no signiﬁcant difference in allelic genotype
frequency of position 221 of the promoter between patients and
controls. And at position +4 of the promoter, allele Q was only
detected in the infectious diseases group and a frequency
comparison could not be made. In this study no ﬁrm conclusions
could be drawn regarding the relationships between pediatric
infections and mutations at positions 221 and +4 of the promoter,
and further studies with larger samples are needed.
As a result of linkage disequilibrium, only seven haplotypes –
HYPA, HYPB, LYPA, LYPB, LXPA, LXPB, and LYQA – of the MBL2 gene
were found in all 256 of the study subjects. Haplotype HYPA was
predominant in both patients and controls, which conﬁrms the
results of a previous similar study in an Asian population.14 In the
present study, the frequency of the haplotype HYPA, related to
higher MBL protein levels, was statistically lower in the patients
than in the controls (p = 0.003); in contrast, the frequency of the
haplotype LYPB, related to lower MBL protein levels, was
signiﬁcantly higher in patients than in the controls (p = 0.017).
As regards the promoter and structural combined genotype of the
MBL2 gene, the frequencies of the ‘YA-type’, related to higher
serum MBL levels, and the ‘XB-type’, related to lower serum MBL
levels, were signiﬁcantly different between patients and controls
(p = 0.041). The above ﬁndings of this study support the view that
genetic polymorphisms of the MBL2 gene are related to common
infectious diseases in pediatric patients.The effective biological function of MBL depends on the protein
level in the circulatory system. In many studies, low serum MBL
levels have been conﬁrmed to be associated with increased
susceptibility to infectious diseases.15–17 Comparing serum MBL
levels between each infectious disease group and healthy controls
in this study, we found that serum MBL levels of the patients with
active CMV infection were signiﬁcantly lower than those of
controls (p = 0.019). At the same time, an interesting reverse result
was found in serum MBL levels of the patients with ARI and
localized abscess, which were higher than those of controls
(p = 0.030 and p = 0.021, respectively). Considering that MBL is an
acute phase protein and the concentration has been shown to
increase to between 1.5- and 3-fold as a result of a stress
response,18 serum MBL levels of the patients detected in this study
were theoretically a little higher than the pre-infection levels of the
same subjects. Although serum MBL levels might be modiﬁed by
the presence of infection, the function of MBL in susceptibility to
infection, determined by serum pre-infection levels, could still be
evaluated. In the case of this study, serum MBL levels of the
patients with active CMV infection in the pre-infection phase were
predictably lower than those of controls. Therefore, it appears that
low serum MBL levels may play a role in the high sensitivity of
pediatric CMV infections. It has also been reported in a previous
study that an MBL deﬁciency may be a signiﬁcant risk factor for the
development of CMV infection in kidney transplant recipients.19
On the other hand, it was hard to evaluate the function of MBL in
susceptibility to ARI and localized abscess in this study because of
the higher MBL levels in the patients with these two infectious
diseases. An additional convalescent sample should be collected
from each patient for reference in any further studies on the
relationship between serum MBL levels and infection.
R. Tao et al. / International Journal of Infectious Diseases 16 (2012) e403–e407 e407The cut-off values deﬁning MBL deﬁciency have not been
determined, with 500 ng/ml20 sometimes suggested, but in some
cases 100 ng/ml21 or 1000 ng/ml22 have also been used. Despite the
controversy regarding the deﬁnition of MBL deﬁciency, it is a
certainty that changes in the oligomeric structure and reduced
binding to carbohydrate ligands in mutant MBL compared with
wild-type MBL accounts for the biological phenotype in MBL-
deﬁcient individuals.1 However, a large proportion of the popula-
tion with an MBL deﬁciency is still asymptomatic, indicating that
MBL deﬁciency alone may not cause people to be susceptible to
infection, but may act as a cofactor in some individuals.23 On the
basis of this study and other studies researching MBL as a single
factor of susceptibility to infection, the association between
infection and MBL deﬁciency with other coexisting immunodefects
requires further exploration.
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